

South Carolina  
Department of Health and Human Services  
1801 Main Street  
Columbia, South Carolina 29201-8206

**Pharmacy and Therapeutics (P&T) Committee Meeting**  
**August 7, 2024**  
MINUTES

- I. Welcome and Call to order..... Dr. Edward Behling, MD
- Called to order at 4:03pm

*Freedom of Information Act/Americans with Disabilities Act Compliance Pledge – This body's official minutes will indicate that this meeting is in compliance with the Freedom of Information Act's mandate that the public be notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.*

- II. Roll Call ..... Kimberly Bristow, RPh
- Informed committee that Thomas Phillips, RPh has resigned. Committee members were encouraged to attend future meetings in person.

**Committee Members Present:**

Edward Behling, MD	Kelly Barth, DO	Duncan Norton, MD
Cheryl Hartvigsen, RPh	Divya Ahuja, MD	Heather Hembree, PharmD
Katherine Lewis, MD	Garrett Whittle, PharmD	Jony Bolinger, MD
Patricia Witherspoon, MD	Kimberly Rudd, MD	Oscar Lovelace, MD

**SC DHHS Staff:**

Sarah Hearn-Bailey, Esq.  
Kevin Wessinger, MD  
Kimberly Bristow, RPh  
Brandie Crider, BSBA, CPhT  
Tawanna Zeigler, MHSA, CPhT  
Ashley Sirianni, DNP, FNP-BC

**Magellan/PRIME:**

Lori Ash  
Blake Cook, RPh  
Manisa Bulsara, PharmD  
Lisa Correll, PharmD  
Alexis Jones, MHA, MA, CPhT

- III. Approval of Minutes from June 12, 2024..... P&T Committee
  - The draft minutes from the previous P&T Committee meeting June 12, 2024, were emailed to the members for review prior to the meeting.
    - Kelly Barth, DO motioned to approve the previous P&T meeting minutes and Divya Ahuja, MD seconded the motion for approval. The minutes were approved unanimously.
  
- IV. State Updates ..... Dr. Kevin Wessinger and Kimberly Bristow, RPh
  - Dr. Wessinger gave updates on the single PDL (Preferred Drug List) launch. Kimberly informed committee members of PHE unwinding which ends 9/30/2024 and provided updates on COVID-19 tests, vaccine and reimbursements. Kimberly also stated \$0 copayments for Medicaid beneficiaries was effective 7/1/24.
  
- V. Pharma Updates..... Lisa Correll, PharmD
  - Lisa introduced two new team members Manisa Bulsara, PharmD and Alexis Jones, MHA, MA, CPhT. Lisa also informed the committee that the invites have been sent for Pharma Days and meetings which are virtual for 40 minutes each and there is one meeting per entity per year.
  
- VI. New Drugs to Market..... Manisa Bulsara, PharmD
  - Ohtuvayre™ (ensifentrine)
  - Iqirvo®(elafibranor)
  - Duvyzat™ (givinostat)
  - Rytelo™ (imetelstat)
  - Imdelltra™ (tarlatamab-dlle)
  - Xolremdi™ (mavorixafor)
  
- VII. Classes for Review..... Manisa Bulsara, PharmD
  - Rho Kinase Inhibitors
    - No speaker/presenter.
    - Adding Rhopressa® (netarsudil) and Rocklatan® (netarsudil/latanoprost) as preferred.
    - Duncan Norton, MD motioned for it to be approved, and Divya Ahuja, MD seconded the motion for approval. This change was approved unanimously.
  - Sickle Cell Gene Therapy
    - Biran Patel, PharmD from Bluebird Bio presented on Lyfgenia™.
      - Duncan Norton, MD asked about the therapy treatment plan for Lyfgenia™ and if it was pediatric approved. The speaker will provide that information by email.

- Adding Lyfgenia™ (lovotibeglogene autotemcel) and Casgevy® (exagamglogene autotemcel) as preferred. [Class Level PA (Prior Authorization) will be in effect]
  - Dr Wessinger noted to the committee members that gene therapy agents are not typically associated with outpatient covered medications. In 2025, CMS will implement a mechanism for states to use Value Based/ Outcomes Based Agreements for gene therapies and start with sickle cell gene therapy agents.
- Jony Bolinger, MD motioned for this to be approved, and Oscar Lovelace, MD seconded the motion for approval. This change was approved unanimously.
- Rectal Anticonvulsants
  - No speaker/presenter.
  - Adding Diastat Acudial® (diazepam), Diastat Pedi System® (diazepam), and Diazepam rectal gel system as preferred.
  - Oscar Lovelace, MD motioned for this to be approved, and Jony Bolinger, MD seconded the motion for approval. This change was approved unanimously.

VIII. Drug Classes for Re-Review ..... Manisa Bulsara, PharmD

- Multiple Sclerosis
  - Shirley Quach, PharmD from Novartis presented on Kesimpta®.
    - Oscar Lovelace, MD asked for the number of relapses in the timeframe of the controlled group compared to the treatment group. The speaker will get that raw data and provide that information by email.
  - Split Multiple Sclerosis category into Oral and Injectables.
  - Oral Multiple Sclerosis Agents: Adding Dalfampridine (generic for Ampyra®), Fingolimod (generic for Gilenya™), and Teriflunomide (generic for Aubagio®) as preferred.
  - Injectable Multiple Sclerosis Agents: Adding Kesimpta® (ofatumumab) as preferred. [Drug Level PA (Prior Authorization) will be in effect]
  - Katherine Lewis, MD and Duncan Norton, MD motioned for this to be approved, and Divya Ahuja, MD seconded the motion for approval. This change was approved unanimously.
- Hypoglycemia Agents
  - No speaker/presenter.
  - Adding Baqsimi® (glucagon) nasal powder, Glucagon 1mg injection, Glucagon 1mg emergency kit, Gvoke Hypopen® (glucagon), Proglycem® (diazoxide) oral suspension, and Zegalogue® (dasiglucagon) autoinjector/syringe as preferred.

- Adding Glucagon emergency kit (Fresenius Kabi), Diazoxide suspension, and Gvoke® (glucagon) vial/syringe as non-preferred.
- Oscar Lovelace, MD motioned for this change to be accepted and Kelly Barth, DO seconded the motion for approval. This change was approved unanimously.
- Bladder Antispasmodics
  - No speaker/presenter.
  - Adding Fesoterodine ER (generic for Toviaz®) and Myrbetriq® tablet as preferred.
  - Adding Toviaz® tablet as non-preferred.
  - Oscar Lovelace, MD motioned for this change to be accepted and Duncan Norton, MD seconded the motion for approval. This change was approved unanimously.

IX. Old Business ..... P&T Committee

- No old business

X. New Business..... P&T Committee

- Divya Ahuja, MD expressed some areas to discuss about single PDL (preferred drug list). He will email them for review.

XI. PDL (Preferred Drug List) Housekeeping..... Manisa Bulsara, PharmD

- Corticosteroids are now split by topical potency.
- Effective dates for everything presented will be January 1, 2025, except for Sickle Cell Gene Therapy which will be effective November 1, 2024.
- New mailbox: scpharma@primetherapeutics.com

XII. Next P&T Meeting will be held on Wednesday, November 6, 2024, at 4pm.

- All P&T Committee members are encouraged to attend in person.

XIII. Adjournment

- Meeting adjourned at 5:13pm.